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Background. Herpesviruses can be neutralized in vitro but remain infectious in immune hosts. One difference between these
settings is the availability of immunoglobulin Fc receptors. The question therefore arises whether a herpesvirus exposed to
apparently neutralizing antibody can still infect Fc receptor
+ cells. Principal Findings. Immune sera blocked murine gamma-
herpesvirus-68 (MHV-68) infection of fibroblasts, but failed to block and even enhanced its infection of macrophages and
dendritic cells. Viral glycoprotein-specific monoclonal antibodies also enhanced infection. MHV-68 appeared to be
predominantly latent in macrophages regardless of whether Fc receptors were engaged, but the infection was not abortive
and new virus production soon overwhelmed infected cultures. Lytically infected macrophages down-regulated MHC class I-
restricted antigen presentation, endocytosis and their response to LPS. Conclusions. IgG Fc receptors limit the neutralization
of gamma-herpesviruses such as MHV-68.
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INTRODUCTION
Persistent viruses typically transmit infection by reactivating in
immune hosts. Thus, they differ fundamentally from epidemic
viruses, whose replication and transmission are blocked by
established immunity. The chief defence against epidemic viruses
is neutralizing antibody [1], which mainly blocks receptor binding
[2]. How persistent viruses evade the same neutralization is not
well understood. Some employ antigenic variation [3], but
herpesviruses-arguably the most sophisticated of all persistent
viruses-do not do so to any significant degree. Herpes virions are
shed at low levels, while anti-viral antibody titers are often high
[4]. And in vitro neutralization is abundantly documented [5–8].
However, virus carriers still spread infection. Standard in vitro
neutralization assays therefore fail to capture some important
aspects of infection in vivo.
Our understanding of gamma-herpesvirus neutralization has
been limited by the narrow species tropisms of Epstein-Barr virus
(EBV) and the Kaposi’s Sarcoma-associated Herpesvirus (KSHV).
Both fail to reproduce their basic pathogenesis in experimental
animals and propagate poorly in vitro, making related gamma-
herpesviruses an important source of information. One of the
most experimentally accessible is murine gamma-herpesvirus-68
(MHV-68), a natural, B cell-tropic parasite of yellow-necked mice
[9–12]. The basic mechanisms of host colonization appear to be
quite similar between these viruses. However, their diseases are
not-EBV and KSHV cause tumours, whereas MHV-68 patholo-
gies primarily reflect lytic replication [13,14]. Thus, MHV-68
models normal gamma-herpesvirus biology much better than it
does human disease. Distinguishing normal host colonization from
disease is important in pathogenesis studies. CD4
+ T cells [15,16],
CD8
+ T cells [17] and antibody [16,18–20] can all protect against
MHV-68-induced disease, because viral immune evasion operates
poorly at high levels of lytic replication [21,22]. But host immunity
fails to block herpesvirus transmission, because evasion dominates
at low levels of lytic replication [21,22].
Our aim with MHV-68 is to understand why established
antibody responses do not prevent gamma-herpesvirus trans-
mission. Standard MHV-68 pathogenesis studies have a limited
capacity to answer this question as they focus on acute infection;
by the time MHV-68-specific antibody is made, virus titers are
low. And no MHV-68 transmission model yet exists. Immune sera
protect antibody-deficient mice against disease [16,18–20], so
antibody can damp down pathological lytic replication. But these
studies have not distinguished neutralization from antibody-
dependent cytotoxicity. Comparison with Herpes simplex virus
[23] would suggest that mainly the latter protects against disease
[24]. In contrast, blocking transmission must require neutraliza-
tion.
It is essential with MHV-68 not only to record in vivo
phenomena but to identify the mechanisms behind them.
Fortunately, MHV-68 offers several advantages for in vitro analysis:
it is readily propagated and modified, cells with relevant
deficiencies can be derived from knockout mice, and monoclonal
antibodies can be generated from virus carriers. Our approach has
therefore been first to understand as much as possible about
neutralization in vitro. Immune sera appear to block MHV-68
infection of fibroblasts [25,26] primarily by blocking cell binding
[27]. This raises questions about the robustness of neutralization,
as antibody-coated viruses could still potentially infect macro-
phages and dendritic cells via immunoglobulin Fc receptors (FcRs)
[28,29]. MHV-68 replicates in both these cell types [30,31]. And
FcRs on intraepithelial dendritic cells [32] or epithelial FcRn
[33,34] could allow antibody-coated virions to enter new hosts.
We have tested here whether antibody-mediated MHV-68
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+ and FcR
2 cells. Our data
suggest that FcRs allow otherwise neutralized virions to remain
infectious and are therefore likely to compromise infection control.
RESULTS
Immune sera fail to block MHV-68 infection of Fc
receptor
+ cells
Immune sera block MHV-68 infection of fibroblasts [25,26]. In
order to test whether this neutralization applied also to FcR
+ cells,
we incubated MHV-68 virions with sera from immune mice and
then added the antibody-coated virions to either BHK-21
fibroblasts or RAW264.7 macrophages (Fig. 1). The virus used
(BAC
+) expresses eGFP from a human cytomegalovirus (HCMV)
IE1 promoter, so eGFP expression provides a convenient marker
of infection [35]. Immune sera inhibited BHK-21 cell infection but
enhanced RAW264.7 cell infection (Fig. 1A, 1B). Naive sera had
no effect (Fig. 1B), and neither heating immune sera (1 h, 56uC)
nor adding exogenous mouse complement to untreated or heat-
treated sera altered infection enhancement (data not shown). The
enhancement was less obvious for peritoneal macrophages
(Fig. 1C). However, all sera (n.20) blocked fibroblast infection
and failed to block RAW264.7 cell or peritoneal macrophage
infections. Dendritic cell infection, this time measured by eGFP-
tagged gM expression rather than HCMV IE1-driven eGFP, was
also enhanced rather than blocked by immune serum (Fig. 1D).
Immune sera enhanced BAC
+ MHV-68 infection of wild-type,
bone marrow-derived macrophages, but inhibited the infection of
IgG FcR-deficient macrophages (Fig. 2). Thus, the failure of
antibody to inhibit macrophage infection was due to IgG FcRs,
and RAW264.7 cell infection represented a general phenomenon
of FcRs undermining virus neutralization.
Viral glycoprotein-specific monoclonal antibodies
(mAbs) can also enhance MHV-68 infection of Fc
receptor
+ cells
Immune sera comprise complex mixtures of antibody specificities,
titers and isotypes. Thus, while they provide a useful measure of
the overall host response, different components of that response
can be hard to discern. For example, sera might contain both
infection inhibiting and infection enhancing antibodies. We
therefore tested a range of MHV-68 glycoprotein-specific mAbs
for FcR-dependent infection (Fig. 3). Almost all glycoprotein-specific
IgG mAbs enhanced RAW264.7cellinfection byBAC
+ MHV-68 to
somedegree.Gp150-specificmAbswerethemosteffective,butsome
enhancement could be seen even with mAbs specific for the
neutralization targets gH/gL [27] and gB [36] (Fig. 3A). Although
we did not have sufficient mAbs for comprehensive testing, IgM
mAbs tended to inhibit infection and IgG2a mAbs enhanced better
than IgG1 or IgG2b (Figure 3B). As with serum-mediated
enhancement, mAb-mediated enhancement was much reduced
with FcR-deficient macrophages (Fig. 3C, 3D).
Increased viral eGFP expression correlates with
other measures of infection
Since the behaviour of an HCMV IE1 promoter in the context of
the MHV-68 genome is unknown, we tested whether BAC
+ eGFP
expression in RAW264.7 cells correlated with other markers of
infection (Fig. 4). First, preincubating virions with a glycoprotein-
specific mAb also gave more eGFP
+ cells when eGFP expression
was driven by an endogenous MHV-68 promoter (Fig. 4A). We
used that of ORF73, since it is active in latency as well as in lytic
Figure 1. Immune sera enhance MHV-68 infection of Fc receptor
+
cells. A. BAC
+ MHV-68 virions (4610
6PFU/ml) were incubated (1 h,
37uC) with sera from MHV-68-immune C57BL/6 mice. The serum/
antibody mixtures were then added to BHK-21 fibroblasts (1PFU/cell) or
RAW264.7 macrophages (3PFU/cell). 18h later infection was measured
by flow cytometry of viral eGFP expression. Each line corresponds to 1
serum sample, pooled from 2 mice. The data are from 1 of 5 equivalent
experiments. B. An equivalent experiment using sera from naive or
MHV-68-immune BALB/c mice was analyzed by fluoresence microscopy.
Each picture shows a 50% confluent culture of RAW264.7 cells. EGFP
+
cells appear black. C. BAC
+ MHV-68 virions and immune serum (20 mL/
3610
5PFU) were incubated together (1 h, 37uC) and then divided
between BHK-21 cells (0.3PFU/cell), murine embryo fibroblasts (MEF,
0.3PFU/cell), RAW264.7 cells (1PFU/cell) and peritoneal macrophages
(1PFU/cell). Viral eGFP expression in each population was determined
18h later by flow cytometry. The data are from 1 of 3 equivalent
experiments. CD19
+ peritoneal cells were always ,1% eGFP
+. D. Bone
marrow-derived dendritic cells or 293T epithelial cells were infected
with MHV-68 (3PFU/cell) that expressed eGFP-tagged gM and had been
pre-treated with 1% MHV-68-immune or naive mouse serum. 21 h later,
gM-eGFP expression was quantitated by flow cytometry. Dendritic cells
were CD11c
+ and co-stained for MHC class II as shown.
doi:10.1371/journal.pone.0000560.g001
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+ cells. A. Purified BAC
+ virions (10
6PFU/ml)
were incubated (1 h, 37uC) either alone (virus only) or with isotyped-matched mAbs (all IgG2a at 10 mg/ml): gp150-T1A1, gH/gL-T2C12, gB-T7H9,
gp48-6D10. MAbs LP2 (anti-HSV gD) and W6/32 (Anti-HLA-ABC) provided negative controls. The virion/antibody mixtures were added to RAW264.7
cells (3PFU/cell). Infection was quantitated 18h later by flow cytometry of viral eGFP expression. The data shown are representative of .10 different
experiments with at least 4 different mAbs tested for each viral protein. T2C12 is a neutralizing mAb, but 10 mg/ml corresponds to a sub-neutralizing
dose for the amount of virus used. B. BAC
+ MHV-68 virions were incubated (1 h, 37uC) with no serum (virus only), 1% MHV-68-immune serum (imm
serum), or mAbs of different isotypes as indicated (10 mg/ml) and then added to RAW264.7 cells (5PFU/cell). Viral eGFP expression was quantitated by
flow cytometry 18h later. The data are from 1 of 5 equivalent experiments. C. Wild-type (WT) and FceRIc
2/2FccRIIB
2/2 (FcR
2/2) bone marrow-derived
macrophages were incubated overnight with BAC
+ MHV-68 virions plus mAb dilutions as shown. T1A1 and T4G2 recognize gp150, 58-16D2
recognizes gp60 and Y3 is an H2-K
b-specific control. The dashed lines show infection with no antibody for WT (coarse dashes) and FcR
2/2
macrophages (fine dashes). The data are from 1 of 3 equivalent experiments. D. Wild-type (WT) or CD16
2/2CD32
2/2CD64
2/2 (FcR
2/2) bone marrow-
derived macrophages were left uninfected (nil) or infected (3PFU/cell) with BAC
+ virions that had been preincubated or not (virus only) with gp150-
specific mAbs as shown (T4G2, T1A1). Infection was quantitated 18 h later by flow cytometric assay of viral eGFP expression. Virus alone typically
gave eGFP expression in 1–2% of bone marrow macrophages. The bars show mean6SD results from 3 experiments.
doi:10.1371/journal.pone.0000560.g003
Figure 2. The effect of immune serum on
macrophage infection depends on IgG Fc recep-
tors. Wild-type and FceRIc
2/2FccRIIB
2/2 (FcR
2/2)
bone marrow-derived macrophages were incubat-
ed overnight with BAC
+ MHV-68 (5PFU/cell) that
had been preincubated with dilutions of serum
from either naive or MHV-68-immune mice, and
then analyzed for viral eGFP expression by flow
cytometry. The dashed lines show the level of
infection with no antibody. The data are from 1 of
3 equivalent experiments.
doi:10.1371/journal.pone.0000560.g002
MHV-68 in Macrophages
PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e560infection [37,38]. Second, a gp150-specific mAb increased both
the dissemination of BAC
+ eGFP to new cells (Fig. 4B) and BAC
+
virus replication (Fig. 4C). FcR-dependent infection was therefore
productive. Third, real-time PCR showed that pre-incubation with
antibody increased the uptake of viral genomes (Fig. 4D) and
eGFP-tagged (gM-eGFP) virions (Fig. 4E). Comparing neutral and
low pH washes suggested mAbs primarily increased virus binding
(Fig. 4F).
HCMV IE1 promoter activity underestimates
macrophage infection
Although HCMV IE1 promoter-driven eGFP expression corre-
lated with other measures of infection, it was unclear whether all
infected cells were eGFP
+ and whether eGFP expression
correlated mainly with lytic or latent viral gene expression. There
is currently no definitive marker of MHV-68 latency. Thus, to test
whether some eGFP
2 cells might also be infected we exploited the
fact that the HCMV IE1 promoter is activated by LPS [39] and
treated RAW264.7 cells exposed to MHV-68 with LPS (Fig. 5A).
The number of eGFP
+ cells increased considerably. This was true
even when LPS was added after removing the input virus, so it did
not act by increasing infection. Instead, the HCMV IE1 promoter
was active in only a minority of MHV-68-infected RAW264.7
cells. The same was true of peritoneal macrophages (see Fig. 6A).
LPS had no effect on eGFP expression from the MHV-68 ORF73
promoter (data not shown).
This result raised the possibility that increased eGFP expression
by antibody reflected greater reporter gene expression as well as
greater infection. We therefore tested the effect of antibody on
BAC
+ eGFP expression in RAW264.7 cells with and without LPS
(Fig. 5B). LPS increased eGFP expression in all samples, but the
increase was similar for each. And adding neutralized HSV-1/
IgG2a complexes to MHV-68-infected RAW264.7 cells did not
increase their eGFP expression, arguing that Fc receptor
engagement had little effect on the HCMV IE1 promoter. Thus,
although HCMV IE1 promoter activity underestimated the total
number of infected macrophages, it gave a good relative indication
of infection in different populations, and this was increased by
antibody. The fold increase in BAC
+ eGFP expression clearly
depends in part on the basal level, so the fold increase in
RAW264.7 cell infection was lower when LPS was included, in
Figure 4. Antibody-dependent infection is productive and correlates
with increased cell binding. A. MHV-68 expressing eGFP via an IRES
inserted downstream of ORF73 was incubated with viral glycoprotein-
specific mAbs as shown (100 mg/ml) and then incubated with
RAW264.7 cells (5PFU/cell). UI=uninfected; vir only=virus without
antibody. 18 h later viral eGFP expression was quantitated by flow
cytometry. The data are from 1 of 3 equivalent experiments. B. BAC
+
MHV-68 was incubated with the gp150-specific mAb T4G2 (20 mg/ml)
or with medium alone (1 h, 37uC) and then added to RAW264.7 cells
r
(5PFU/cell). The cells were washed with PBS after 2h and then added to
a 5-fold excess of uninfected RAW264.7 cells to monitor viral spread.
Replicate cultures were analyzed for eGFP expression at the time points
indicated. C. Replicate samples from the experiment in B, either with (+)
or without (2) mAb preincubation for the initial infection, were divided
into cell and supernatant (sup) fractions, frozen and thawed, and plaque
assayed for infectious virus. The data are from 1 of 2 equivalent
experiments. D. MHV-68 virions were incubated (1 h, 37uC) with 20 mg/
ml mAb T4G2 (VIR+mAb) or with medium alone (VIR only), then added
to RAW264.7 cells (8 h, 37uC). The cells were then washed in pH=3
citrate buffer to remove accessible virus and lysed. Viral DNA content
was quantitated by real-time PCR. Each bar shows mean6SD of 4
replicates. The data are from 1 of 2 equivalent experiments. E. MHV-68-
gM-GFP was pre-incubated with mAb T1A1 (100 mg/10
7PFU) (dotted
line) or with medium only (1 h, 37uC) (dashed line), then added to
RAW264.7 cells (5PFU/cell). The cells were washed with PBS after 4 h at
37uC, and assayed for gM-eGFP uptake by flow cytometry. F. gM-eGFP
MHV-68 was incubated with RAW264.7 cells at different multiplicities
with or without the gp150-specific mAb T7F5 (10 mg/ml). 4h later the
cells were washed either in PBS or in pH=3 citrate buffer (acid). gM-
eGFP uptake was then assayed by flow cytometry. The data are from 1
of 2 equivalent experiments.
doi:10.1371/journal.pone.0000560.g004
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enhancement between these cell types may reflect that the HCMV
IE1 promoter is more active in explanted primary macrophages.
Again, the key point is not enhancement, but that in the presence
of FcRs immune sera failed to neutralize.
Most macrophages showing HCMV IE1 promoter
activity are not lytically infected
Our second question was whether BAC eGFP
+ macrophages
predominantly supported lytic or latent infection. We answered
this by immunostaining infected peritoneal macrophages for the
ORF65 capsid component (Fig. 6). Perinuclear capsids were
observed in both eGFP
+ and eGFP
2 macrophages, consistent with
endocytic virion uptake [36], but very few of either showed the
strong nuclear staining typical of new capsid expression, as was
seen in lytically infected BHK-21 cells (Fig. 6A, 6C). Thus, most
BAC eGFP
+ macrophages appeared to be latently infected. This
was also true of RAW264.7 cells, consistent with RAW264.7 cell
cultures infected with BAC
+ MHV-68 and .50% eGFP
+
containing much less infectious virus and surviving much longer
than equivalent BHK-21 cell cultures (data not shown).
Even BHK-21 cells showed a limited correlation between BAC
eGFP expression and nuclear capsid staining (Fig. 6A). Thus, the
HCMV IE1 promoter operated independently of the rest of the
MHV-68 genome: eGFP
+ cells were not necessarily lytic, and
neither lytic nor latent cells were necessarily eGFP
+. In contrast,
the expression of eGFP-tagged gM from the endogenous gM
promoter correlated closely with ORF65 expression (Fig. 6B, 6C),
as is also seen in infected BHK-21 cells [36]. The gM-eGFP virus
therefore allowed us to identify lytically infected macrophages.
The contrast between BAC
+ eGFP and gM-eGFP was also
evident for a virus that expressed both (Fig. 7). They can be
distinguished because gM and gN concentrate in the trans-Golgi
network and are excluded from the nucleus [35,40]-examples are
indicated in Figure 7A-whereas free eGFP distributes uniformly.
LPS treatment made gM-eGFP difficult to detect and massively
increased BAC
+ eGFP. gM-eGFP may have been partly obscured
by the increase in BAC
+ eGFP, but LPS also reduced gM-eGFP
expression (see the eGFP
+ populations in Fig. 9A). The marked
overall increase in total eGFP expression with LPS (Fig. 7B)
therefore indicated that many MHV-68-exposed macrophages
were infected but gM-eGFP
2. These were presumably latently
infected.
Functional characterization of MHV-68-infected
macrophages
MHV-68-infected macrophage cultures evidently contain a mix-
ture of uninfected, lytically infected and latently infected cells.
Assays of function that fail to distinguish these populations are
therefore hard to interpret. We focussed on the lytic (gM-eGFP
hi)
infection phenotype. Flow cytometry established that approxi-
mately 50% of lytically infected RAW264.7 cells had down-
regulated cell surface MHC class I expression (Fig. 8A). Similar
results were obtained for peritoneal macrophages (data not
Figure 5. LPS reveals higher levels of RAW264.7 cell infection for both antibody-independent and antibody-dependent infections. A. RAW264.7
cells were left uninfected (UI) or incubated overnight with BAC
+ MHV-68 virions (2PFU/cell). LPS (100 ng/ml) was added to the infected cells for the
full 18h, for 4h following infection, or not at all (virus only). Viral eGFP expression was then quantitated by flow cytometry. The bars show mean6SD
of 3 replicate cultures. Equivalent results were obtained in 3 repeat experiments with RAW264.7 cells and 3 further experiments with peritoneal
macrophages. B. RAW264.7 cells were incubated overnight with BAC
+ MHV-68 virions (2PFU/cell) with no LPS, with LPS for 4h before assay, or with
LPS for the whole 18h. There was either no additional treatment (virus only), or the cultures were supplemented with the gp150-specific mAb T1A1
(10 mg/ml) or with LP2-treated HSV-1 virions. LP2, kindly provided by Ms. S.Bell (Division of Virology), is a gD-specific IgG2a neutralizing mAb and was
added at concentrations sufficient to ablate HSV-1 infectivity (data not shown). Viral eGFP expression was measured by flow cytometry. The data are
from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000560.g005
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became more obvious. This was consistent with K3 function, since
the MHV-68 K3 degrades TAP more efficiently in cells treated
with IFN-c [41]. K3 function was confirmed by comparing
antigen presentation from peritoneal macrophages infected with
wild-type and K3 knockout viruses (Fig. 8B): K3 disruption
markedly increased the stimulation of a lytic antigen-specific T cell
hybridoma. Comparison with a peptide titration curve suggested
that K3 reduced antigen presentation 10-100-fold. The population
with intermediate eGFP expression in Fig. 8A presumably derived
its gM-eGFP from incoming virions or phagocytosed infected cell
debris, and contained both latently infected and uninfected cells
(see Figure 7). These showed no evidence of MHC class I down-
regulation. Thus, K3 may not be transcribed in latently infected
macrophages.
Lytically infected RAW264.7 cells showed similar spontaneous
TNF-a expression to uninfected cells (Fig. 9A), but less increase in
expression with LPS. They also failed to up-regulate IL-6 or
Figure 6. gM-eGFP expression but not HCMV IE1 promoter-driven eGFP expression correlates with ORF65 capsid expression in MHV-68-infected
macrophages. A. Peritoneal macrophages or BHK-21 fibroblasts were infected with BAC
+ MHV-68 (2PFU/cell and 0.5PFU/cell respectively). The
macrophages were also treated or not with LPS (100 ng/ml). 18h later the cells were fixed in 4% paraformaldehyde and stained with the ORF65-
specific mAb 12B8 plus Alexa 568-coupled goat anti-mouse IgG pAb (red). Nuclei were counterstained with DAPI (blue). eGFP was visualized directly
(green). The data are from 1 of 3 equivalent experiments, and similar results were obtained with RAW264.7 cells. B. Peritoneal macrophages were
infected as in A but with MHV-68 expressing eGFP-tagged gM, then fixed and stained for ORF65. The data are from 1 of 3 equivalent experiments,
and similar results were obtained with RAW264.7 cells. C. RAW264.7 cells were left uninfected (UI) or infected overnight (2PFU/cell) with either BAC
+
or gM-eGFP MHV-68. The cells were stimulated with LPS (100 ng/ml) for a further 4 h to maximize HCMV IE1 promoter activity, then fixed,
permeabilized with 0.1% Tween-20 and stained for ORF65 with mAb 12B8 plus Alexa 633-conjugated goat anti-mouse IgG pAb. Control=secondary
antibody only. The percentage of cells in each quadrant is shown. The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000560.g006
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infected RAW264.7 cells may no longer respond to LPS. Lytically
infected RAW264.7 cells also showed less endocytic uptake of
fluorochrome-labelled dextran or 0.2 mm beads (Fig. 9B). Based
on LPS-stimulated, BAC eGFP expression, many of the cells in the
Fig. 9 cultures would have been latently infected. In contrast to
lytic infection, this was not associated with obvious functional
abnormalities.
DISCUSSION
Immune responses generally protect against gamma-herpesvirus-
induced disease but fail to prevent viral transmission. Viral
inhibition of antigen presentation provides a window of T cell
escape [22]. But how do virions evade neutralization by antibody
when they are shed from immune hosts? This is different to
evading antibody-dependent cytotoxicity within hosts. Indeed, the
gammaherpesviruses, which colonize single hosts mainly by
latency-associated lymphoproliferation [42], lack the IgG FcR
homologs associated with evading antibody-dependent cytotoxicity
[43]. Here we have shown that immune sera fail to block FcR-
mediated MHV-68 infection. Thus, while the natural antibody
response blocks cell binding [27], it evidently fails to inactivate the
key process of membrane fusion. Accessory uptake routes such as
that provided by FcRs may therefore allow gammaherpes virions
to remain infectious when leaving immune hosts.
Virions leaving a persistently infected host or entering a new,
naive host traverse complex, dynamic environments. Precisely
what infection opportunities and obstacles they encounter are
unknown. However, immune hosts shed only small numbers of
virions and can have quite high antibody titers, both in serum and
mucosal secretions [44]. Exiting virions should therefore meet
sufficient antibody to neutralize them if neutralization were
efficient. MHV-68 neutralization was clearly limited in scope.
Neutralizing mAbs can block fusion [27,35], but are quite rare in
virus carriers and do not work well. Thus, the whole response
blocks fusion poorly. We focussed on serum antibody, but the
specificities in mucosal secretions are unlikely to be substantially
different. Immunoglobulin transport may enrich mucosal secre-
tions for IgA, but the IgA response to MHV-68 is minimal [45]
and much of the KSHV-specific antibody in mucosal secretions is
IgG [46]. Serum antibody is therefore probably not dissimilar to
what an exiting virus would meet.
If epithelial binding is blocked by antibody, antigen sampling
and immunoglobulin homeostasis at mucosal surfaces could
provide important routes of infection. It might even be considered
that the normal infectious particle is an antibody-coated virion.
FcRn takes up IgG in adults as well as neonates [33]; FcR
+
myeloid cells access the mucosal lumen [32]; and M cells provide
transcytosis to submucosal FcRs [47]. The fate of incoming virions
may therefore depend on their capacity to infect after FcR-
mediated uptake. We studied the fate of antibody-coated MHV-68
in macrophages because the destruction of antibody-coated
particles is a major part of their function. Antibody-coated
MHV-68 escaped this fate. Thus, MHV-68 should be able to
escape from the endosomes of other cells too, indeed it normally
infects fibroblasts via a low pH-dependent endocytic route [27].
We saw no obvious functional difference between antibody-
independent and antibody-dependent macrophage infections. In
both cases, MHV-68 remained largely latent for at least 24h, as
measured by an absence of lytic gene expression. Latently infected
macrophages were functionally indistinguishable from uninfected
controls. On switching to lytic infection, MHV-68 inhibited
a range of macrophage functions, including MHC class I-restricted
antigen presentation, and produced new virions. Thus, FcR-
mediated uptake fully restored the infectivity of virions coated with
serum antibody. The uptake of antibody-coated viruses by lectins
[48] may achieve the same end.
Once MHV-68 has entered a new host, there is no detectable
viraemia [49] and viruses lacking gp150, which have a defect in
virion release [50], or lacking gL, which have a defect in virion
binding [51], appear remarkably normal. Host colonization
therefore depends more on cell/cell spread and virus-driven B
cell proliferation than on the release of cell-free virions. The
capacity of immune serum to damp down lytic replication in this
setting probably reflects antibody-dependent cytotoxicity. Howev-
er, antibody could also divert infection from epithelial cells and
fibroblasts, where it is predominantly lytic, to FcR
+ cells, where it
Figure 7. BAC+eGFP and gM-eGFP are differentially affected by LPS.
A. RAW264.7 cells were infected with BAC
+gM-eGFP
+ MHV-68 (2PFU/
cell, 18 h), then treated for 4 h with LPS (100 ng/ml). The cells were
then fixed and examined for eGFP expression (green). Nuclei were
counterstained with DAPI (blue). The thick arrows show gM-eGFP
+ cells
and the thin arrows BAC
+ eGFP
+ cells. B. RAW264.7 cells were infected
with BAC
+gM-eGFP
+ MHV-68 at different multiplicities. 18 h later the
cells were treated for 4 h with LPS (100 ng/ml). Total eGFP expression
(BAC
+ eGFP plus gM-eGFP) was then quantitated by flow cytometry.
doi:10.1371/journal.pone.0000560.g007
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without an anti-viral effect. Such considerations emphasize the need
to understand the molecular mechanisms behind in vivo phenomena.
These are rarely so straightforward as they first appear.
MATERIALS AND METHODS
Mice and cells
BALB/c and C57BL/6J mice were purchased from Harlan U.K.
Ltd. (Bicester, U.K.), housed in the Cambridge University
Department of Pathology and infected intranasally with
2610
4PFU MHV-68 when 6–8 weeks old (Home Office Project
Licence 80/1579). Immune sera were collected at 3–6 months
post-infection, by which time the viral load and serum antibody
have reached steady state [25,26]. Macrophages were derived
from bone marrow progenitors by culture in RPMI with 10% fetal
calf serum, 5% horse serum, 50 mM 2-mercaptoethanol, 2 mM
glutamine, 100U/ml penicillin, 100 mg/ml streptomycin, 1 mM
pyruvate and 20% L929-conditioned medium. New medium was
supplied every 3–4 d and the adherent cells (.95% CD11b
+F4/
80
+) harvested after 7–14 d. Peritoneal macrophages were
obtained by peritoneal lavage of naive mice with Dulbecco’s
modified Eagle medium plus 5% fetal calf serum. Cells not
adherent to tissue culture plates (45 min, 37uC) were discarded.
The adherent cells were 80–85% CD11b
+CD11c
2F4/
80
+CD19
2. In flow cytometry-based assays, FSC/SSC gating
increased this to .95%. Dendritic cells were grown from bone
marrow progenitors in RPMI with 10% fetal calf serum, 50 mM2 -
mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin
and 7.5ng/ml GM-CSF. Bone marrow cells were first put on tissue
culture plates (30 min, 37uC) and the adherent (macrophage-rich)
cells discarded. The culture medium was changed every 2d. After
3d, non-adherent (granulocyte-rich) cells were discarded. After 7d,
the non-adherent cells (90% CD11c
+MHC class II
+Gr1
2) were
harvested. BHK-21 cells, RAW264.7 cells and 293T cells were
grown in Dulbecco’s modified Eagle medium with 2 mM
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and
10% fetal calf serum. Murine embryo fibroblasts were cultured in
the same medium plus 50 mM 2-mercaptoethanol.
Viruses
Infectious MHV-68 was derived from a genomic BAC, which
contains eGFP with an HCMV IE-1 promoter as part of a loxP-
flanked BAC cassette [35]. Except when eGFP expression was
used as a marker of infection (BAC
+ virus), the BAC cassette was
removed by passaging the virus through NIH-3T3-CRE cells [21].
MHV-68 expressing either eGFP fused to the C-terminus of
glycoprotein M or eGFP downstream of ORF73 via an IRES have
been described [35,38]. All viruses were grown in BHK-21 cells.
Figure 8. MHV-68 inhibits MHC class I-restricted antigen presentation in macrophages. A. RAW264.7 cells were infected overnight with gM-eGFP
MHV-68 (2PFU/cell), treated or not with IFNc (20 U/ml) for a further 24 h, then stained for cell surface MHC class I. The data are from 1 of 2 equivalent
experiments. B. Peritoneal macrophages from C57BL/6 mice were left uninfected (UI), infected overnight with wild-type (WT) or K3-deficient (K3
2)
MHV-68 at different multiplicities, or incubated with dilutions of the immunodominant H2-D
b-restricted MHV-68 peptide p56, to relate viral
recognition to an equivalent peptide concentration. A p56-specific lacZ
+ T cell hybridoma was added the next day and b-galactosidase expression
assayed by ELISA after a further 20 h. Each bar shows mean6SD results of triplicate cultures. The data are from 1 of 2 equivalent experiments. Similar
results were also obtained with bone marrow-derived macrophages.
doi:10.1371/journal.pone.0000560.g008
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centrifugation (10006g, 3 min). Virions were then concentrated
from supernatants by high speed centrifugation (380006g,9 0m i n ) .
Virus titers were determined by plaque assay on BHK-21 cells [48].
Flow cytometry
Cells exposed to eGFP
+ viruses were washed in PBS and analysed
directly for green fluorescence. To assay endocytosis, macrophages
were incubated with Alexa 647-conjugated 10kDa dextran
(Invitrogen) at 100 mg/ml or 0.2 mm Crimson (625/645) Fluo-
spheres (Invitrogen) at 2610
9 beads/ml, washed in PBS and
analysed for red fluorescence. For surface staining, cells were
incubated (1h, 4uC) with MHV-68 glycoprotein-specific mAbs
followed by fluorescein-conjugated rabbit anti-mouse IgG pAb
(Dako Cytomation) or Alexa 633-conjugated or Alexa 488-
conjugated goat anti-mouse IgG pAb (Invitrogen). Fluorescent
conjugates of mAbs against CD86, CD11c, CD11b, F4/80, MHC
Figure 9. Lytically infected macrophages show multiple functional abnormalities. A. Peritoneal macrophages were infected overnight with gM-
eGFP MHV-68 (2PFU/cell), treated or not with LPS (100 ng/ml) for a further 6h in the presence of brefeldin-A, then fixed, permeabilized and stained
for IL-6 or TNF-a. Cells infected and stimulated the same way, but without brefeldin-A, were stained for CD86 without permeabilization. The data are
from 1 of 2 equivalent experiments. B. Peritoneal macrophages were left uninfected or infected overnight with gM-eGFP MHV-68 (2PFU/cell), then
incubated with 0.2 mm Crimson (625/624) Fluospheres or Alexa 647-conjugated dextran (molecular weight 10 kDa). After 90 min at 4uC (for no
endocytosis) or 37uC (for endocytosis) the cells were washed and analyzed by flow cytometry. The infected populations were gated according to high
gM-eGFP expression (thick red lines, corresponding to lytic infection) or low gM-eGFP expression (thin black lines, corresponding to no infection or
latent infection) and then assayed for red fluorescence. The data are from 1 of 3 equivalent experiments.
doi:10.1371/journal.pone.0000560.g009
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intracellular cytokine staining, cells were fixed in 1% para-
formaldehyde (30 min), permeabilized with 0.1% saponin, and
incubated with phycoerythrin-conjugated rat anti-mouse IL-6 or
anti-mouse TNF-a mAbs (BD Biociences). For ORF65 staining,
cells were permeabilized in 0.1% Tween-20 after fixation and
incubated with mAb 12B8 followed by Alexa 633-conjugated goat
anti-mouse IgG pAb. Cells were washed with PBS after antibody
staining and analysed on a FACS Calibur using Cellquest software
(BD Biosciences).
Immunofluorescence
Adherent cells were washed in PBS, fixed in 2% paraformalde-
hyde and permeabilized with 0.1% Tween-20. EGFP fluorescence
was visualized directly. The MHV-68 ORF65 capsid component
was stained with mAb 12B8 [36] plus Alexa 568-conjugated goat
anti-mouse IgG pAb (Invitrogen). Nuclei were counterstained with
DAPI. Fluorescence was visualized with an Olympus IX70
microscope plus a Retiga 2000R camera line (QImaging).
Monoclonal antibodies
MHV-68 glycoprotein-specific hybridomas were all derived from
MHV-68-infected mice by fusing spleen cells with NS0 cells [52].
Their specificities were determined by flow cytometric analysis of
cells infected with wild-type or glycoprotein-mutant viruses, or
transfected with recombinant glycoproteins. The mAbs used in
this study are listed in Table 1. Isotypes were determined by
ELISA (Sigma Chemical Co.). Antibody was concentrated from
hybridoma supernatants by ammonium sulfate precipitation and
quantitated by ELISA using isotype-matched standards.
Viral DNA quantitation
DNA was extracted from infected cells and a portion of the MK3
ORF (genomic co-ordinates 24832-25071) amplified by real-time
PCR [38]. PCR products were quantitated with Sybr green
(Invitrogen) and compared with a standard curve of cloned
template. K3 content was normalized by comparison with beta
actin, amplified from replicate samples.
Antigen presentation assay
Peritoneal macrophages from C57BL/6 (H2
b) mice were infected
with wild-type or K3-deficient [21] MHV-68 (2PFU/cell) or
incubated with p56 peptide, which corresponds to an immuno-
dominant H2-D
b-restricted MHV-68 epitope from ORF6 [57].
18h later a T cell hybridoma was added which produces b-
galactosidase in response to p56+H2-D
b [59]. After a further 18h,
the cells were washed61 in PBS and lysed in PBS/5 mM MgCl2/
1% NP-40/0.15 mM chlorophenol-red-beta-D-galactoside (Merck
Biosciences) to assay beta-galactosidase activity. The absorbance at
595nm was read on a Biorad Benchmark Microplate Reader.
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